Between COVID-19 severity and its prevention – what should rheumatologists be aware of?
More details
Hide details
Department of Rheumatology, Medical University of Lodz, Poland
Online publication date: 2021-09-08
Reumatologia 2021;(Konferencja Pacjent post-COVID-owy. Co zostaje, a co się zmienia? 1):1-2
A year has passed since the unprecedented eruption of SARS-CoV-2 infections affected almost all countries around the world. Rheumatic patients represent a numerous group of people in which the immune system is impaired both by chronic immunosuppressive treatment and by the disease itself. For this reason doctors are worried about the optimal management and how to prevent the exacerbation of autoimmune systemic diseases.
Recently, a few important studies have been published regarding the risk of a severe course of COVID amongst rheumatic patients, parallel to the dynamically ongoing worldwide vaccination process as never seen before.
Zhong J, Shen G, Yang H, et al. COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study. Lancet Rheumatol 2020; 2: E557–E564, DOI: 10.1016/S2665-9913(20)30227-7.
FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis 2020; annrheumdis-2020-218310, DOI: 10.1136/annrheumdis-2020-218310 [Online ahead of print].
Strangfeld A, Schäfer M, Gianfrancesco MA, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2021; annrheumdis-2020-219498, DOI: 10.1136/annrheumdis-2020-219498 [Online ahead of print].
Marques CDL, Kakehasi AM, Pinheiro MM, et al. High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry. RMD Open 2021; 7: e001461, DOI: 10.1136/rmdopen-2020-001461.
Fitzgerald GE, Maguire S, Haroon N. COVID-19: What Do Rheumatologists Need to Know? Curr Rheumatol Rep 2021; 23: 5, DOI: 10.1007/s11926-020-00971-y.
Opinc A, Łukasik Z, Makowska J. The attitude of Polish rheumatology patients towards telemedicine in the age of the COVID-19 pandemic. Reumatologia 2020; 58:134–141, DOI: 10.5114/reum.2020.96665.
Jorge A, D’Silva KM, Cohen A, et al. Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study. Lancet Rheumatol 2021; 3: E131–E137, DOI: DOI:10.1016/S2665-9913(20)30422-7.
Subesinghe S, Bechman K, Rutherford AI, et al. A Systematic Review and Metaanalysis of Antirheumatic Drugs and Vaccine Immunogenicity in Rheumatoid Arthritis. J Rheumatol 2018; 45: 733–744, DOI: 10.3899/jrheum.170710.
Park JK, Lee YJ, Shin K, et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis 2018; 77: 898–904, DOI: 10.1136/annrheumdis-2018-213222.
Hua C, Barnetche T, Combe B, Morel J. Effect of methotrexate, anti-tumor necrosis factor , and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2014; 66: 1016–1026, DOI: 10.1002/acr.22246.
Shimabukuro TT, Cole M, Su JR. Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US – December 14, 2020–January 18, 2021. JAMA 2021, DOI: 10.1001/jama.2021.1967 [Online ahead of print].
Sokolowska M, Eiwegger T, Ollert M, et al. EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines. Allergy 2021, DOI: 10.1111/all.14739 [Online ahead of print].
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Journals System - logo
Scroll to top